Using flow cytometry and multiplex immunohistochemistry, the investigators identified a distinct intratumoral natural killer cell population in melanoma tumors with a phenotype resembling decidual NK cells. These cells were defined as CD56Bright CD16− CD49a+ CD9+, a profile consistent with a decidual-like program that in physiology supports placentation and immune tolerance at the maternal–fetal interface. The authors refer to this population as decidual-like NK (dl-NK) cells.
These dl-NK cells were detected within tumor tissue and in peritumoral areas. In contrast, the same phenotype was rare or absent in peripheral blood samples from both patients with melanoma and healthy donor controls, indicating the dl-NK population is primarily an intratumoral phenomenon in the contexts examined by the study.
The dl-NK population was observed across samples from both male and female patients. Detection extended across different melanoma subtypes and across anatomical sites, including primary tumors, lymph node deposits, and distant metastatic lesions. The study therefore reports dl-NK cells as a feature present in diverse clinical and anatomic settings within the melanoma cohort analyzed.
Because CD9 is a defining marker of decidual NK cells, the investigators examined tumor CD9 expression in relation to intratumoral dl-NK frequency. They report a positive association between tumor CD9 expression and dl-NK frequency, with Pearson rho = 0.40 and p = 0.056. This result indicates a moderate positive correlation in the dataset; the reported p value is near but does not meet conventional thresholds for statistical significance.
In an exploratory set of patients receiving tumor-infiltrating lymphocyte (TIL) therapy, the authors note that the single patient with progressive disease showed a higher dl-NK frequency. The source does not provide additional systematic outcome correlations or larger-scale treatment-response analyses.
To probe mechanisms underlying dl-NK presence in tumors, the authors co-cultured healthy donor NK cells with CD9-expressing melanoma cell lines. Direct co-culture induced robust acquisition of CD9 by CD56Bright NK cells from healthy donors. When NK cells and melanoma cells were physically separated by a transwell membrane, CD9 acquisition did not occur, indicating that direct cell–cell interaction is necessary for this phenotypic change under the experimental conditions described.
These in vitro findings support a model in which melanoma cells can contribute to the emergence of a decidual-like NK phenotype in situ via contact-dependent processes leading to CD9 transfer or induction on NK cells.
The authors interpret the presence of dl-NK cells within melanomas, together with tumor-driven CD9 acquisition, as evidence of an immunologic parallel between the melanoma microenvironment and the maternal–fetal interface. In physiological decidua, NK cells adopt features that promote tolerance and support tissue remodeling. The study raises the possibility that tumors may exploit similar NK cell programs to influence the tumor microenvironment, although functional consequences of dl-NK enrichment in melanoma (for example, impact on anti-tumor immunity or tumor progression) were not comprehensively reported in the source.
Primary experimental approaches reported in the source include flow cytometry and multiplex immunohistochemistry to define NK cell phenotypes in tumor and blood specimens, and co-culture assays with and without transwell separation to test requirements for CD9 acquisition. Patient and donor samples came from institutional biobanks and clinical repositories: healthy donor peripheral blood mononuclear cells were obtained via the Human Immune Tissue Network Biobank and plateletpheresis leukoreduction filters were purchased from a blood center. Melanoma blood and tumor samples were collected under the Melanoma Biorepository at the University of Colorado Cancer Center.
The study reports ethical approval from the Colorado Multiple Institutional Review Board. The source confirms that participant consent procedures and relevant approvals were obtained and archived per institutional requirements.
Funding for the work was declared from Golfers Against Cancer and the National Institutes of Health (R21 CA297312 and R01 AI158410). Conflicts of interest were disclosed for two authors; the remaining authors declared no conflicts.
The source reports key observations but does not provide exhaustive functional or clinical outcome data linking dl-NK frequency to patient prognosis or therapy response beyond the single noted TIL-treated patient with progressive disease. The statistical association between tumor CD9 expression and dl-NK frequency is reported with Pearson rho = 0.40 and p = 0.056; the p value is borderline and the source does not report additional validation cohorts or mechanistic dissection beyond the described co-culture/transwell experiments. Detailed mechanistic pathways for CD9 transfer, long-term consequences for NK cell function, and broader clinical significance remain to be defined and were not reported in the source.